Skip to main content
. 2024 Apr 2;47(9):2339–2349. doi: 10.1007/s40618-024-02320-7

Fig. 2.

Fig. 2

ADAS-Cog test primary endpoint at baseline, 16 and 32 weeks of treatment in both study arms. Effect of treatment on ADAS-Cog score at baseline, 16 and 32 weeks, after correction for baseline value, in total population (n = 31) (A), males (n = 15) (B) and females (n = 16) (C). Estimated means ± SEM derived from GLM are shown. P-values for treatment effect are reported in the graph